Obermatt
See Similar Stocks →

Pfizer Limited

NSI:PFIZER · INE182A01018
PharmaceuticalsMedium

360

65
Medium confidence — indicative
Profit price30
Owner Earnings Yield76
Dividend Yield1
Price/Sales36
EV / Gross Profit23
Price/Book20
Return on Capital95
Cash Return on Capital92
Return on Equity80
EBIT Margin95
Gross Profitability59
Cash Conversion51
Owner Earnings Margin93
Sales growth28
Profit Growth75
Long-Term EPS Growth50
Reinvestment75
Price momentum28
Debt load77
Refinancing72
Debt Payback100
Liquidity97
Analyst ratings100
Opinion Changes98
Price Target Upside32
Market mood41
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Pfizer Limited clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNSEI
Founded1950
Employees323
Websitepfizerltd.co.in
ISININE182A01018
Last UpdateApr 2, 2026
Index & Theme
UrologyCardiovascularHematologyPain ManagementCentral Nervous SystemNeurologyVaccinesOncologyHealth CareManufacturingPharmaceutical

Description

Pfizer Limited, a subsidiary of Pfizer Inc., operates in the pharmaceutical sector, focusing on the research, development, manufacturing, and distribution of a wide range of medications and vaccines. Business Segments The company operates through d…

Analysis

Quality compounder

Pfizer Limited earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 25.5×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 9% a year, against analyst forecasts of 4%. The gap between price and consensus is worth watching: demanding expectations.

Growth is tepid; the safety picture is sturdy. The company scores 13/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
72
2023202420252026

All-time high

79

Mar 2026

All-time low

11

Jan 2023

Average rank

53

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
36
19
14
16
Price/Earnings
19
53
39
37
Price/Book
20
55
45
31
Dividend Yield
1
60
63
60
Value (overall)
6
55
39
33

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pfizer Limited with its peers
Zoetis
NYQ:ZTS
56
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Phathom Pharmaceuticals
NSQ:PHAT
37
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Omeros
NMQ:OMER
29
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →